Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GBR 310
- Development stage
- Discontinued
- Lead developer
- Glenmark Pharmaceuticals
- Modality
- Hydrogel Systems → Drug Delivery Systems, Small Molecules
- Administration
- Ophthalmic
01
Overview
GBR 310 is a long-acting, sustained-release formulation of **latanoprost**, a prostaglandin F2-alpha analogue, developed by **Graybug Vision** (formerly GrayBug) for the treatment of **glaucoma** and ocular hypertension. The drug is encapsulated in proprietary **polymeric microparticles** designed to be administered via a single intravitreal or subconjunctival injection, providing therapeutic levels of the medication for up to six months. This delivery system aims to overcome the significant challenge of patient non-compliance associated with daily eye drop regimens. While GBR 310 was an early lead candidate for Graybug, the company later shifted its focus to other pipeline assets such as GB-102 and GB-401, and GBR 310 is no longer listed in the company's active development pipeline.
- Other names
- Latanoprost sustained-release Graybug
02
Targets
IgE (Immunoglobulin E)
Beyond the preview
Go deeper on GBR 310.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GBR 310.